Patents by Inventor Longgui Wang
Longgui Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220009889Abstract: The present invention relates to a novel crystal form, manufacturing procedures, pharmaceutical compositions, formulations and medicaments comprising a N-methylisoindigo crystalline, methods of preparation, and the use of the N-methylisoindigo crystalline to prepare a medicament to prevent cancer, or treat cancer or an inflammatory-related disease associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines.Type: ApplicationFiled: November 21, 2019Publication date: January 13, 2022Inventor: Longgui Wang
-
Patent number: 9962400Abstract: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.Type: GrantFiled: June 6, 2014Date of Patent: May 8, 2018Assignee: Natrogen Therapeutics International, Inc.Inventors: Longgui Wang, Simon K. Mencher
-
Publication number: 20150335617Abstract: The present invention is directed to topical compositions and methods for topically treating psoriasis comprising meisoindigo as an active ingredient. The topical compositions preferably further comprise skin penetration enhancers, pharmaceutical surfactants and solubility enhancers, oil phase components, aqueous phase components, emulsifiers, moisturizers, antioxidants, vitamins, lubricants, herbal extracts, preservatives, and other ingredients. In addition to meisoindigo, the compositions may comprise other agents commonly used to topically treat psoriasis. The disclosed methods have been demonstrated to effectually treat moderate and severe forms of psoriasis to a degree similar to a potent corticosteroid without side effects. Preferably, the method involves topical application of the disclosed compositions to affected epidermal areas twice a day. In addition, the disclosed methods may be used in conjunction with other common therapies in the treatment of psoriasis.Type: ApplicationFiled: July 29, 2015Publication date: November 26, 2015Inventors: Longgui Wang, Xiao Mei Liu, Simon K. Mencher, James P. McCarron, JR.
-
Publication number: 20150231115Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 4, 2015Publication date: August 20, 2015Inventors: Longgui Wang, Xiao Mei Liu, Lian Mo, Simon K. Mencher, James P. McCarron, JR.
-
Patent number: 9040574Abstract: The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-?3,3?-dihydroindole-2,2? diketone; N-1-(?-D-O-triacetyl-xylopranosyl)-?3,3?-dihydroindole-2,2? diketone; and N-1-(?-D-O-triacetyl-xylopranosyl)-N?-methyl-?3,3?-dihydroindole-2,2? diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.Type: GrantFiled: September 20, 2012Date of Patent: May 26, 2015Assignee: Natrogen Therapeutics International, Inc.Inventors: Longgui Wang, Simon K. Mencher, James P. McCarron, Jr.
-
Patent number: 9023885Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.Type: GrantFiled: March 8, 2013Date of Patent: May 5, 2015Assignee: Natrogen Therapeutics International, Inc.Inventors: Longgui Wang, Xiao Mei Liu, Lian Mo, Simon K. Mencher, James P. McCarron, Jr.
-
Publication number: 20140356373Abstract: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.Type: ApplicationFiled: June 6, 2014Publication date: December 4, 2014Applicant: NATROGEN THERAPEUTICS INTERNATIONAL, INC.Inventors: Longgui Wang, Simon K. Mencher
-
Patent number: 8748475Abstract: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.Type: GrantFiled: August 3, 2011Date of Patent: June 10, 2014Assignee: Natrogen Therapeutics International, Inc.Inventors: Longgui Wang, Simon K. Mencher
-
Patent number: 8563525Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.Type: GrantFiled: December 20, 2010Date of Patent: October 22, 2013Assignee: Natrogen Therapeutics International, Inc.Inventors: Longgui Wang, Xiao Mei Liu, Lian Mo, Simon K. Mencher, James P. McCarron, Jr.
-
Patent number: 8394847Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.Type: GrantFiled: August 26, 2009Date of Patent: March 12, 2013Assignee: Natrogen Therapeutics International, Inc.Inventors: Longgui Wang, Xiao Mei Liu, Lian Mo, Simon K. Mencher, James P. McCarron, Jr.
-
Publication number: 20120070518Abstract: The present invention is directed to topical compositions and methods for topically treating psoriasis comprising meisoindigo as an active ingredient. The topical compositions preferably further comprise skin penetration enhancers, pharmaceutical surfactants and solubility enhancers, oil phase components, aqueous phase components, emulsifiers, moisturizers, antioxidants, vitamins, lubricants, herbal extracts, preservatives, and other ingredients. In addition to meisoindigo, the compositions may comprise other agents commonly used to topically treat psoriasis. The disclosed methods have been demonstrated to effectually treat moderate and severe forms of psoriasis to a degree similar to a potent corticosteroid without side effects. Preferably, the method involves topical application of the disclosed compositions to affected epidermal areas twice a day. In addition, the disclosed methods may be used in conjunction with other common therapies in the treatment of psoriasis.Type: ApplicationFiled: September 21, 2011Publication date: March 22, 2012Applicant: NATROGEN THERAPEUTICS INTERNATIONAL, INC.Inventors: Longgui Wang, Xiao Mei Liu, Simon K. Mencher, James P. McCarron, JR.
-
Publication number: 20120058121Abstract: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.Type: ApplicationFiled: August 3, 2011Publication date: March 8, 2012Applicant: NATROGEN THERAPEUTICS INTERNATIONAL, INC.Inventors: Longgui Wang, Simon K. Mencher
-
Publication number: 20110160157Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.Type: ApplicationFiled: December 20, 2010Publication date: June 30, 2011Applicant: NATROGEN THERAPEUTICS INTERNATIONAL, INC.Inventors: Longgui Wang, Xiao Mei Liu, Lian Mo, Simon K. Mencher, James P. McCarron, JR.
-
Patent number: 7855223Abstract: The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-? or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.Type: GrantFiled: July 26, 2006Date of Patent: December 21, 2010Assignee: Natrogen Therapeutics International, Inc.Inventors: Ruihuan Chen, Simon K. Mencher, Allen Tsao, Xiao Mei Liu, Longgui Wang
-
Publication number: 20100098702Abstract: The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-?3,3?-dihydroindole-2,2? diketone; N-1-(?-D-O-triacetyl-xylopranosyl)-?3,3?-dihydroindole-2,2? diketone; and N-1-(?-D-O-triacetyl-xylopranosyl)-N?-methyl-?3,3?-dihydroindole-2,2? diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.Type: ApplicationFiled: September 16, 2009Publication date: April 22, 2010Inventors: Longgui Wang, Simon K. Mencher, James P. McCarron
-
Publication number: 20090325895Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 26, 2009Publication date: December 31, 2009Inventors: Longgui Wang, Xiao Mei Liu, Lian Mo, Simon K. Mencher, James P. McCarron, JR.
-
Patent number: 7582670Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.Type: GrantFiled: April 13, 2005Date of Patent: September 1, 2009Assignee: Natrogen Therapeutics, Inc.Inventors: Longgui Wang, Xiao Mei Liu, Lian Mo, Simon K. Mencher, James P. McCarron, Jr.
-
Publication number: 20070027203Abstract: The present invention is directed to a method for treating inflammatory arthritis in a mammal. The method typically comprises administering to an animal a therapeutically effective amount of at least one compound selected from indigo, isoindigo, indirubin or derivatives thereof, such as NATURA-? or NATURA. The present invention is further directed to pharmaceutical compositions that include a therapeutically effective amount of at least one compound of the invention, an anti-inflammatory arthritis agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 26, 2006Publication date: February 1, 2007Inventors: Ruihuan Chen, Simon Mencher, Allen Tsao, Xiao Mei Liu, Longgui Wang
-
Publication number: 20050197381Abstract: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 13, 2005Publication date: September 8, 2005Inventors: Longgui Wang, Xiao Liu, Lian Mo, Simon Mencher, James McCarron
-
Patent number: 6933315Abstract: A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Methods of synthesizing these derivatives is also taught. In addition, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal having solid tumor cancer. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.Type: GrantFiled: June 10, 2004Date of Patent: August 23, 2005Inventors: Longgui Wang, Xiaomei Liu, Ruihuan Chen